Table 6. KF41399 effects on antitumor... | American Society of Hematology

Table 6.

KF41399 effects on antitumor activity of ACNU against human lung carcinoma Lu-65 inoculated into nude mice

Group	Dose (mg/kg)	Schedule (day)	T/C^6-150 (%)	Body weight^6-151 (g)	Mortality	Platelet counts (×10⁴/μL^6-152)
Control			100	1.2	0/5	90.3 ± 16.4
KF41399	25 (PO)	0-2	95	1.7	0/5	94.0 ± 35.4
ACNU	45 (IV)	3-4	17^6-153	−4.5	0/5	45.2 ± 24.7^6-153
KF41399 + ACNU	25 (PO)	0-2
	45 (IV)	3-4	54^6-153	−0.5	0/5	139.2 ± 25.1^6-153
KF41399 + ACNU	25 (PO)	0-2
	45 (IV)	3-4	27	−2.9	0/5	95.7 ± 28.9

Group	Dose (mg/kg)	Schedule (day)	T/C^6-150 (%)	Body weight^6-151 (g)	Mortality	Platelet counts (×10⁴/μL^6-152)
Control			100	1.2	0/5	90.3 ± 16.4
KF41399	25 (PO)	0-2	95	1.7	0/5	94.0 ± 35.4
ACNU	45 (IV)	3-4	17^6-153	−4.5	0/5	45.2 ± 24.7^6-153
KF41399 + ACNU	25 (PO)	0-2
	45 (IV)	3-4	54^6-153	−0.5	0/5	139.2 ± 25.1^6-153
KF41399 + ACNU	25 (PO)	0-2
	45 (IV)	3-4	27	−2.9	0/5	95.7 ± 28.9

PO, oral; IV, intravenous.

LC-6 cells (8-mm³ fragment) were inoculated into BALB/c nu/nu mice. When tumors grew to a size between 50 and 300 mm³, therapy was initiated.

Minimum T/C;

maximum body weight change;

platelet counts on day 10;

P < .05.